Ποια είναι η τιμή για ABVC BioPharma, Inc. (ABVC)

Η τιμή για ABVC BioPharma, Inc. (ABVC) είναι $0.93

Ποια είναι η κεφαλαιοποίηση αγοράς για ABVC BioPharma, Inc. (ABVC)

Η κεφαλαιοποίηση αγοράς για ABVC BioPharma, Inc. (ABVC) είναι $24.18M

ABVC BioPharma, Inc. (ABVC) Τιμή και Κεφαλαιοποίηση Αγοράς

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Η τιμή για ABVC	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$204,198 $24.18M	NVDA	$5.309T	+21,956,696.03%
$177,826 $24.18M	AAPL	$4.624T	+19,120,922.49%
$158,492 $24.18M	GOOG	$4.121T	+17,042,072.46%
$138,121 $24.18M	MSFT	$3.591T	+14,851,669.95%
$107,395 $24.18M	AMZN	$2.792T	+11,547,793.98%

Η τιμή για ABVC

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$204,198 $24.18M